1403.7: A Phase 0/1a study of brigimadlin (MDM2-p53 antagonist) concentrations in brain tissue and a non-randomized, open-label, dose-escalation study of brigimadlin in combination with radiotherapy in patients with newly diagnosed glioblastoma^1–3

Zoom

1. Sarkaria J, et al. ASCO 2023. Poster TPS2081; 2. NCT05376800. https://clinicaltrials.gov/ct2/show/NCT05376800. Accessed September 2023; 3. Boehringer Ingelheim. Data on file.